



FW: The Inside Angle - September 2024 Issue

From Gilchrist, David <dgilchri@amgen.com>

Date Sun 11/3/2024 9:28 AM


To Dave Gilchrist <daveg14@hotmail.com>

From: Global Oncology Communications <global-oncology-communications@success.amgen.com>

Sent: Friday, September 27, 2024 5:24 PM

To: Gilchrist, David <dgilchri@amgen.com>

Subject: The Inside Angle - September 2024 Issue



Showcasing the Latest Oncology Updates from Q3

1 New IMDELLTRA™ Presentations Garner Enthusiastic Response at WCLC

Amgen presented exciting new data for IMDELLTRA™ (tarlatamab-dlle), our first-in-class DLL3-targeting BiTE® molecule, at the 2024 World Conference on Lung Cancer (WCLC), held Sept. 7-10 in San Diego. Highlights included results from the global Phase 1b DeLLphi-303 study, showing the potential of IMDELLTRA combined with PD-L1 inhibitors as first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC). Amgen also presented long-term follow-up data from the Phase 2 DeLLphi-301 study, demonstrating sustained safety and efficacy. These findings further emphasize IMDELLTRA's exciting role in treating this aggressive cancer. Read the release [here](#).



**2024 World Conference
on Lung Cancer**

**SEPTEMBER 7-10, 2024
SAN DIEGO, CA USA**

2 Exciting Data from Across the Oncology Portfolio Presented at ESMO



Amgen showcased groundbreaking research from its innovative oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2024, held Sept. 13-17 in Barcelona. With a focus on using cutting-edge molecular approaches to tackle some of the most challenging cancers, Amgen's presentations highlighted investigational treatments. The data underscored our leadership in oncology and commitment to advancing diverse therapies.



Key presentations included:

- First findings from the Phase 1b study of LUMAKRAS[®] plus Vectibix[®] in combination with FOLFIRI in first line (1L) KRAS G12C-mutated metastatic colorectal cancer (mCRC) (#5050) featured in an oral presentation.
- Phase 1 dose escalation and initial dose expansion data from AMG 193 featured during the presidential symposium session (#3482) and simultaneous publication in *Annals of Oncology*, linked [here](#).
- First-in-human study of xaluritamig in men with metastatic castration-resistant prostate cancer (mCRPC) (#1598).

More information on Amgen's presence at ESMO can be found [here](#).

3 Observing Blood Cancer Awareness Month in September



To recognize Blood Cancer Awareness Month (BCAM), Amgen is proud to sponsor the Leukemia & Lymphoma Society's Light the Night walks for 2024. This is more than just a walk; it's our chance to illuminate the path to groundbreaking research and vital support for people impacted by cancer.

From now until November, there are opportunities for you to "step into the light" and get involved. Visit our [National Team Page](#) to join, create or donate to one of our Amgen

teams. Every dollar we raise helps make a difference and brings us closer to a future free from the shadows of cancer.



Additionally, Amgen is educating health care providers on the latest advancements in blood cancer treatment through sponsored content. In our recent sponsored piece in Healio, study investigator Hillard M. Lazarus, MD, FACP, gives his insight on the FDA's recent expanded indication of BLINCYTO® for patients with B-cell precursor acute lymphoblastic leukemia (B-ALL). Read the article [here](#).

DIGITAL ADVERTORIAL

Sponsored Content by Amgen

New Approval Underscores Important Role of Targeted BiTE® Therapy in B-ALL Consolidation Treatment

Amgen
September 17, 2024
12 min read

In 2024 alone, there were an estimated 6,550 new cases of acute lymphocytic leukemia (ALL) and 1,330 estimated deaths due to ALL in the U.S.¹



ALL is actually many different diseases, and one size does not fit all. Patient demographics such as age at onset and the immunophenotype define several different disease subsets, and these varied groups behave as very different diseases.²

— Hillard M. Lazarus, MD, FACP, Professor of Medicine at Case Western Reserve University

4 Amgen Strengthened Advocacy Connections at Annual Stakeholder Summit

In early August, we gathered 70 patient advocacy organizations on Amgen’s Thousand Oaks campus, including several oncology groups. During the event, groups engaged in an Amgen-branded “Add Yours” filter on Instagram and listened to panel discussions on relevant key topics, and select groups were filmed for content to be shared across Amgen channels.



5 A Preview of Rest of Year Activities

Oncology Town Hall

Our next Oncology Town Hall is on Thursday, Oct. 3! Join us as we discuss all the exciting updates coming from Amgen Oncology this quarter. Mark your calendars by clicking on the invite for your region below!

[ATO AND ELMAC INVITE](#)[JAPAC INVITE](#)

Lung Cancer and Gastric Cancer Awareness Month

November is Lung Cancer Awareness Month (LCAM) and Gastric Cancer Awareness Month (GCAM)! Show your support for the lung cancer community by [signing up](#) for LUNGeivity's Breathe Deep TOGETHER 5K on Oct. 26.

For both LCAM and GCAM, Amgen Oncology will be sharing educational content and patient stories throughout the month, so make sure you are following us on social!

Questions/Comments? Please contact David Gilchrist (dgilchri@amgen.com)

Missed a newsletter? [Click here](#) to catch up in our library archive!

Amgen Inc. - FOR INTERNAL USE ONLY. Not for dissemination to the field.

